EU/3/19/2142

Table of contents

About

On 26 February 2019, orphan designation (EU/3/19/2142) was granted by the European Commission to 3R Pharma Consulting GmbH, Germany, for losartan for the treatment of epidermolysis bullosa.

Key facts

Active substance
losartan
Disease / condition
Treatment of epidermolysis bullosa
Date of first decision
26/02/2019
Outcome
Positive
EU designation number
EU/3/19/2142

Sponsor's contact details

3R Pharma Consulting GmbH
Wildbader Strasse 3
Dobel
Baden-Wuerttemberg
75335
Germany
Tel. +49 7083 5276871
E-mail: tobias.zahn@3rpc.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating